Share

January 22, 2013; 80 (4) Article

Differential effect of APOE genotype on amyloid load and glucose metabolism in AD dementia

Rik Ossenkoppele, Wiesje M. van der Flier, Marissa D. Zwan, Sofie F. Adriaanse, Ronald Boellaard, Albert D. Windhorst, Frederik Barkhof, Adriaan A. Lammertsma, Philip Scheltens, Bart N.M. van Berckel
First published December 19, 2012, DOI: https://doi.org/10.1212/WNL.0b013e31827f0889
Full PDF
Citation
Permissions

Make Comment

See Comments

Downloads
269

Share

Article Information

vol. 80 no. 4 359-365
DOI: 
https://doi.org/10.1212/WNL.0b013e31827f0889
PubMed: 
23255822
Published By: 
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
Print ISSN: 
0028-3878
Online ISSN: 
1526-632X
History: 
  • Received June 6, 2012
  • Accepted September 10, 2012
  • First Published December 19, 2012.

Article Versions

Copyright & Usage: 
© 2013 American Academy of Neurology

Author Disclosures

    1. Rik Ossenkoppele, MSc,
    2. Wiesje M. van der Flier, PhD,
    3. Marissa D. Zwan, MSc,
    4. Sofie F. Adriaanse, MSc,
    5. Ronald Boellaard, PhD,
    6. Albert D. Windhorst, PhD,
    7. Frederik Barkhof, PhD,
    8. Adriaan A. Lammertsma, PhD,
    9. Philip Scheltens, PhD and
    10. Bart N.M. van Berckel, PhD
  1. Rik Ossenkoppele, MSc,
    2. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  2. Wiesje M. van der Flier, PhD,
    3. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  3. Marissa D. Zwan, MSc,
    4. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  4. Sofie F. Adriaanse, MSc,
    5. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  5. Ronald Boellaard, PhD,
    6. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  6. Albert D. Windhorst, PhD,
    7. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. SAB member since 3 years of Journal of labelled compounds and radiopharmaceuticals, SAB member since 2 years of Current Radiopharmaceuticals,

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  7. Frederik Barkhof, PhD,
    8. Scientific Advisory Boards:

    1. Scientific consultant to Bayer-Schering, Sanofi- Aventis, Synthon, Novartis, Biogen-Idec, Merck-Serono, GE medical systems, Roche, Janssen, Genzyme

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. Editorial board member for Brain, Eur Radiol, J Neurol, Neuroradiology

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. Serono Symposia speaker 2009, 2010 and 2011, Novartis symposium speaker 2009, 2010 and 2011, BioClinica symposium speaker 2010, Bayer-Schering symposium speaker 2010

    Consultancies:

    1. Consultant for Sanofi-Aventis, Synthon, Janssen, Novartis, Biogen-Idec, GE medical systems, Roche

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. Dutch foundation for MS Research - centre grant 2010-2014

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  8. Adriaan A. Lammertsma, PhD,
    9. Scientific Advisory Boards:

    1. 1. Scientific Advisory Board "Center for Integrated Oncology Köln Bonn" - no compensation received

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. 1. Guest editor Medical Physics, 2. Guest editor International Journal of Molecular Imaging, 3. Section editor Nuklearmedizin, 4. International associate editor Molecular Imaging and Biology, 5. Editorial Board European Joeurnal of Nuclear Medicine and Molecular Imaging, 6. Editorial Board Journal of Cerebral Blood Flow and Metabolism

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. 1. Research support (oncology) by Hoffman-La Roche, 2. Research support (imaging technology) by Philips

    Research Support, Government Entities:

    1. 3. European community grant for FP7 integrative project: INMiND - neuroinflammation in neurodegeneration

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  9. Philip Scheltens, PhD and
    10. Scientific Advisory Boards:

    1. Advisory boards of: Danone Research, Wyeth/Elan, BMS, Genentech, Pfizer, GE healthcare, jansen AI, Merck

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. Lundbeck, educational symposium, 2009, 2012, Nutricia, CTAD 2011 and AAIC 2012, Jansen AI, EFNS 2012

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. Pfizer, GE Healthcare, AVID/Lilly, genentech, Jansen AI, Danone.

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. Alzheimer Nederland; sponsor Alzheimer Center, from 2000 onwards, Stichting VUmc fonds: sponsor Alzheimer Center from 2005 onwards, Innovation Fund: sponsor of Center 2009-2014

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  10. Bart N.M. van Berckel, PhD
    11. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. American health Assistance Foundation, Internationale Stichting Alzheimer onderzoek, Alzheimer Association, Center for Translational Molecular Medicine

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  1. From the Department of Neurology & Alzheimer Center (R.O., W.M.v.d.F., M.D.Z., S.F.A., P.S.), Department of Nuclear Medicine & PET Research (R.O., M.D.Z., S.F.A., R.B., A.D.W., A.A.L., B.N.M.v.B.), and Departments of Epidemiology & Biostatistics (W.M.v.d.F.) and Radiology (F.B.), VU University Medical Center, Amsterdam, the Netherlands.
  1. Correspondence to R. Ossenkoppele: r.ossenkoppele{at}vumc.nl
View Full Text

Article usage

Article usage: December 2012 to July 2021

AbstractFullPdfSource
Dec 2012173022Highwire
Jan 201313131754Highwire
Feb 20133441127Highwire
Mar 20131521211Highwire
Apr 20131331521Highwire
May 20135897Highwire
Jun 20136587Highwire
Jul 20134148Highwire
Aug 20133757Highwire
Sep 20133441Highwire
Oct 20135332Highwire
Nov 20132525Highwire
Dec 20137833Highwire
Jan 201413564Highwire
Feb 20144510Highwire
Mar 20149700Highwire
Apr 20144312Highwire
May 20145931Highwire
Jun 20144111Highwire
Jul 20145722Highwire
Aug 20143725Highwire
Sep 20143311Highwire
Oct 20144112Highwire
Nov 20142811Highwire
Dec 20144902Highwire
Jan 20153833Highwire
Feb 20151800Highwire
Mar 20155214Highwire
Apr 20154622Highwire
May 20157121Highwire
Jun 20157133Highwire
Jul 20155601Highwire
Aug 20155410Highwire
Sep 20154511Highwire
Oct 20153832Highwire
Nov 20154422Highwire
Dec 20154822Highwire
Jan 20164401Highwire
Feb 20163922Highwire
Mar 20164210Highwire
Apr 20161800Highwire
May 20161611Highwire
Jun 20162600Highwire
Jul 20161521Highwire
Aug 20162512Highwire
Sep 20161511Highwire
Oct 20162311Highwire
Nov 20161821Highwire
Dec 20161902Highwire
Jan 20172800Highwire
Feb 20172721Highwire
Mar 20174031Highwire
Apr 20171032Highwire
May 20172200Highwire
Jun 20171100Highwire
Jul 2017611Highwire
Aug 20171411Highwire
Sep 2017932Highwire
Oct 2017900Highwire
Nov 20171310Highwire
Dec 20171110Highwire
Jan 20186411Highwire
Feb 20181912Highwire
Mar 20182901Highwire
Apr 20182600Highwire
May 20183620Highwire
Jun 20182510Highwire
Jul 20182610Highwire
Aug 20182721Highwire
Sep 20182100Highwire
Oct 20182610Highwire
Nov 20184221Highwire
Dec 20183000Highwire
Jan 20192801Highwire
Feb 20192800Highwire
Mar 20191700Highwire
Apr 20192211Highwire
May 20191421Highwire
Jun 20191510Highwire
Jul 20191111Highwire
Aug 20191433Highwire
Sep 20192011Highwire
Oct 20192711Highwire
Nov 20191932Highwire
Dec 20191111Highwire
Jan 20203011Highwire
Feb 20201823Highwire
Mar 20202611Highwire
Apr 20201611Highwire
May 20201110Highwire
Jun 20201611Highwire
Jul 20202212Highwire
Aug 2020900Highwire
Sep 20203221Highwire
Oct 20203800Highwire
Nov 20203850Highwire
Dec 20202910Highwire
Jan 20211700Highwire
Feb 20213901Highwire
Mar 20212313Highwire
Apr 20211800Highwire
May 20211910Highwire
Jun 20211500Highwire

Cited By...

Disputes & Debates: Rapid online correspondence

No comments have been published for this article.
Comment

NOTE: All authors' disclosures must be entered and current in our database before comments can be posted. Enter and update disclosures at http://submit.neurology.org. Exception: replies to comments concerning an article you originally authored do not require updated disclosures.

  • Stay timely. Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • 200 words maximum.
  • 5 references maximum. Reference 1 must be the article on which you are commenting.
  • 5 authors maximum. Exception: replies can include all original authors of the article.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Disputes & Debates Submission Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
Advertisement

Related Articles

Topics Discussed

Alert Me